High KIAA1522 expression predicts a poor prognosis in patients with hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is a highly malignant tumor associated with a poor prognosis, and the molecular mechanisms remain poorly understood. KIAA1522 expression is upregulated in various types of tumor tissue; however, its function remains unknown in HCC. Bioinformatics analysis was undertaken using Oncomine, OncoLnc and other databases, in order to determine KIAA1522 expression in HCC and to analyze its association with postoperative prognosis. Reverse transcription-quantitative PCR was performed to detect KIAA1522 mRNA expression in primary HCC and adjacent normal tissues, while KIAA1522 protein expression was assessed via immunohistochemical staining. KIAA1522 expression and clinicopathological characteristics of primary HCC were evaluated, and their association with patient prognosis was analyzed. The Oncomine database results indicated that KIAA1522 expression in HCC and normal liver tissues was significantly different. RT-qPCR analysis demonstrated that KIAA1522 mRNA expression was significantly higher in HCC tissues compared with that in adjacent normal tissues. Immunohistochemical analysis indicated that expression rate of KIAA1522 protein was significantly higher in primary HCC tissues compared with that in normal liver tissues. The OncoLnc database results demonstrated that KIAA1522 expression was significantly associated with short-term survival. Kaplan-Meier survival analysis indicated that high KIAA1522 protein expression was significantly associated with short-term survival for patients with HCC. Multivariate Cox regression analysis demonstrated that tumor size, Tumor-Node-Metastasis stage and high KIAA1522 protein expression were independent predictors of a poor prognosis in patients with primary HCC. Furthermore, high KIAA1522 expression was significantly associated with postoperative survival time in primary HCC, and thus may be a potential molecular marker for prognosis in patients with this cancer type.

Poor Prognostic Biomarker KIAA1522 Is Associated with Immune Infiltrates in Hepatocellular Carcinoma

“…In order to account for the effects of age and gender on unfavorable outcomes, AFP in serum, univariate, and multivariate analyses were carried out, which suggests that KIAA1522 is a possible prognostic and diagnostic marker. Recent reports [ 14 , 15 ] agree with the findings.…”

“…The mRNA expression of KIAA1522 was elevated in a number of malignancies, according to data from the Gene Expression Atlas and The European Bioinformatics Institute databases, which showed that abnormal KIAA1522 expression may have a role in the pathogenesis and growth of cancer [ 13 ]. Recent research demonstrated that elevated KIAA1522 expression accelerated the evolution of HCC by activating the Wnt/ β -catenin pathway and predicted a poor prognosis in HCC patients [ 14 , 15 ]. The function of KIAA1522 in human cancer immunology, however, has hardly ever been thoroughly examined.…”

Development of novel DNAJB6-KIAA1522-p-mTOR three-protein prognostic prediction models for CRC

“…We previously found that KIAA1522 was overexpressed in non-small cell lung cancer (NSCLC) and was associated with a poor prognosis in patients with NSCLC [25] . In addition, one study suggested that KIAA1522 might be a novel prognostic marker of hepatocellular carcinoma [26] . Recently, Yi et al.…”

“…KIAA1522 is a large protein-coding gene with an uncertain function [23] . It has been reported that the KIAA1522 overexpression has prognostic significance in several cancer types, including CRC [24] , [25] , [26] . Consistently, our earlier findings also suggested that KIAA1522 isa potentialprognostic marker in CRC.…”

Identification and Validation of Hypoxia-Related lncRNA Signature as a Prognostic Model for Hepatocellular Carcinoma

“…Despite the development of surgical resection, liver transplantation, chemotherapy, immunotherapy, and targeted therapy in the therapy of hepatocellular carcinoma, the hepatocellular carcinoma patients’ prognosis is still poor ( Maluccio and Covey, 2012 ; Xu et al, 2020a ). The studies showed that the treatment response and prognosis are influenced by tumor molecular characteristics, although patients own homogeneous clinical risk variables.…”